3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
54
Neoplasm Metastasis
6
Endometrial Neoplasms
6
Polycystic Ovary Syndrome
4
Ovarian Neoplasms
4
Neoplasms
4
Advanced Breast Cancer
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Prostatic Neoplasms
3
Neoplasms by Site
2
Infertility
2
HR+/HER2- Breast Cancer
2
Estrogen Receptor-positive Breast Cancer
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Neoplasms, Male
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sexual Dysfunctions, Psychological
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Low-Grade Serous Ovarian Cancer
1
Low Grade Serous Ovarian Carcinoma
1
Low Grade Serous Ovarian Cancer
1
Locoregional Recurrence
1
Leiomyoma
1
Interventions
Carboplatin
3
durvalumab
2
Tretinoin
2
Paclitaxel
2
Irinotecan
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tegafur-gimeracil-oteracil
1
talazoparib
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Trastuzumab
1
Surgical Procedures, Operative
1
Standard of Care
1
STA 9090
1
SGN-LIV1A
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Letrozole
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled